Skip to Content
Visit ConferenceInsider to read about the AAO2016 cataract topics. Read more

Atropine Sulfate Ophthalmic Ointment

Pronunciation

Dosage Form: ophthalmic ointment

Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.

DESCRIPTION:

 Atropine Sulfate Ophthalmic Ointment USP, 1% is a sterile topical anticholinergic for ophthalmic use. The active ingredient is represented by the chemical structural formula:

(C17H23NO3)2•H2SO4•H2O                                                                     
Mol. wt. 694.84

Chemical name:

Benzeneacetic acid, α-(hydroxymethyl)-, 8-methyl-8-azabicyclo-(3.2.1)oct-3-yl ester, endo-(±)-, sulfate (2:1) (salt), monohydrate.

Each Gram Contains:

Atropine Sulfate Ophthalmic Ointment USP, 1%, contains in each gram of ointment: ACTIVE: Atropine Sulfate USP, 1% (10mg); INACTIVES: White Petrolatum, Mineral Oil, Lanolin Oil and Purified Water.

CHEMICAL PHARMACOLOGY:

The anticholinergic effect of this product blocks the responses of the sphincter muscle of the iris and the accommodative muscle of the ciliary body to cholinergic stimulation, producing pupillary dilation (mydriasis) and paralysis of accommodation (cycloplegia).

INDICATIONS AND USAGE:

For mydriasis and/or cycloplegia. For cycloplegic refraction, for pupillary dilation desired in inflammatory conditions of the iris and uveal tract.

CONTRAINDICATIONS:

This product should not be used in patients with primary glaucoma or a predisposition to narrow anterior chamber angle glaucoma.

This product should not be used in pediatric patients who have previously had a severe systemic reaction to atropine. This product should not be used in those persons showing hypersensitivity to any component of this preparation.

WARNINGS:

In pediatric patients, use with extreme caution. Excessive use in pediatric patients or in certain individuals with a previous history of susceptibility to belladonna alkaloids may produce systemic symptoms of atropine poisoning. If this occurs, discontinue medication, and use appropriate therapy as outlined in “OVERDOSAGE” section.

PRECAUTIONS:

To avoid excessive systemic absorption, the lacrimal sac should be compressed by digital pressure for two to three minutes after instillation. To avoid inducing angle closure glaucoma, an estimation of the depth of the angle of the anterior chamber should be made. Administration of atropine in infants requires great caution.

Patient Warning:

Patients should be advised not to drive or engage in other hazardous activities while pupils are dilated. Patients may experience sensitivity to light and should protect eyes in bright illumination during dilation.


Parents should be warned not to get this preparation in their children’s mouth and to wash their own hands and the child’s hands following administration.

Carcinogenesis, Mutagenesis, Impairment of Fertility:

No studies have been conducted in animals or in humans to evaluate the potential of these effects.

Pregnancy Category C:

Animal reproduction studies have not been performed with atropine. It is also not known whether atropine can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Atropine should be given to pregnant women only if clearly needed.

Pediatric Use:

See "CONTRAINDICATIONS” and "WARNINGS” sections.

ADVERSE REACTIONS:

Prolonged use may produce local irritation characterized by follicular conjunctivitis, vascular congestion, edema, exudate, and an eczematoid dermatitis. Severe reactions are manifested by hypotension with progressive respiratory depression. Coma and death have been reported in the very young.

OVERDOSAGE:

Systemic atropine toxicity is manifested by flushing and dryness of the skin (a rash may be present in pediatric patients),blurred vision, a rapid and irregular pulse, fever, abdominal distension in infants, mental aberration (hallucinosis) and loss of neuromuscular coordination.


Atropine poisoning, although distressing, is rarely fatal, even with large doses of atropine, and is self-limited if the cause is recognized and the atropine medication is discontinued. In severe intoxication, physostigmine salicylate may be administered parenterally to provide more prompt relief of the intoxication. Give physostigmine salicylate as 1-5 mL IV of dilution containing 1 mg in 5 mL of saline. The smaller dose is for pediatric patients, and injection should take not less than two minutes. EKG control is advisable. Dosage can be repeated every five minutes up to a total dose of 2 mg in pediatric patients and 6 mg in adults every 30 minutes. Physostigmine is contraindicated in hypotensive reactions. Atropine (1 mg) should be available for immediate injection if physostigmine causes bradycardia, convulsions or bronchoconstriction. In pediatric patients, the body surface must be kept moist.


Use extreme caution when employing short-acting barbiturates to control excitement.

DOSAGE AND ADMINISTRATION:

ATROPINE SULFATE OINTMENT: A small amount in the conjunctival sac once or twice a day or as directed by a physician.


FOR OPHTHALMIC USE ONLY.

HOW SUPPLIED:

Atropine Sulfate Ophthalmic Ointment USP, 1% is supplied in an ophthalmic tip applicator tube in the following size:

3.5 gm tube - Prod. No. 05134

STORAGE:

Store between 15°- 25°C (59°- 77°F).

KEEP OUT OF REACH OF CHILDREN.

Revised November 2007

Bausch & Lomb Incorporated
Tampa, FL 33637
© Bausch & Lomb Incorporated

PACKAGE/LABEL PRINCIPAL DISPLAY PANEL

NDC 24208-825-55

BAUSCH + LOMB

Atropine

Sulfate

Ophthalmic

Ointment USP,

1% (Sterile)

Rx only

[icon-eye] [icon-1%] [icon-ointment] [icon-3.5gm]

Net wt. 1/8 oz

(3.5g)

ATROPINE SULFATE 
atropine sulfate ointment
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:24208-825
Route of Administration OPHTHALMIC DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
ATROPINE SULFATE (ATROPINE) ATROPINE SULFATE 10 mg  in 1 g
Inactive Ingredients
Ingredient Name Strength
PETROLATUM  
MINERAL OIL  
LANOLIN OIL  
WATER  
Packaging
# Item Code Package Description
1 NDC:24208-825-55 1 TUBE in 1 CARTON
1 3.5 g in 1 TUBE
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
Unapproved drug other 09/30/1990
Labeler - Bausch & Lomb Incorporated (196603781)
Establishment
Name Address ID/FEI Operations
Bausch & Lomb Incorporated 079587625 MANUFACTURE(24208-825)
Revised: 01/2015
 
Bausch & Lomb Incorporated



Hide